Tate Michael Truett 4
4 · Astera Labs, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Astera Labs (ALAB) CFO Tate Michael Truett Sells Shares
What Happened Tate Michael Truett, Chief Financial Officer of Astera Labs (ALAB), disposed of 12,001 shares in multiple open-market transactions on February 17, 2026, generating total gross proceeds of $1,485,784. Breakdown by lot:
- 753 shares @ $122.16 = $91,984
- 4,250 shares @ $122.84 = $522,086
- 3,556 shares @ $123.93 = $440,690
- 2,281 shares @ $124.66 = $284,343
- 1,161 shares @ $126.34 = $146,681
Per the filing footnotes, these were disposals (reported as "S" for sale) but at least some were automatic "sell-to-cover" transactions to satisfy tax withholding obligations tied to the vesting/settlement of previously granted restricted stock units (RSUs), and thus were not discretionary sales by the CFO.
Key Details
- Transaction date: February 17, 2026. Filing date: February 19, 2026 (filed within typical 2-business-day Form 4 window — appears timely).
- Total shares sold: 12,001; total proceeds: $1,485,784.
- Price ranges (per footnotes): groups of shares sold at weighted-average prices with ranges roughly $122.10–$126.34 across the lots (see footnotes F2–F5 for specific subranges and weighted-average details).
- Footnote F1: indicates shares were required to be sold to satisfy tax withholding on RSU vesting ("sell-to-cover").
- Footnote F6: some shares referenced are held by the Tate 1997 Living Trust; the reporting person disclaims beneficial ownership except for any pecuniary interest.
- Shares owned after the transactions are not specified in the provided excerpt of the filing.
Context "Sell-to-cover" sales are routine tax-withholding transactions tied to equity awards and do not necessarily reflect the insider's discretionary view of the company. For retail investors, purchases or direct discretionary sales may be more informative about insider sentiment; this filing primarily documents automated tax-related disposals. The filing does not indicate a 10b5-1 plan or other trading program.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-17$122.16/sh−753$91,984→ 203,331 total - Sale
Common Stock
[F1][F3]2026-02-17$122.84/sh−4,250$522,086→ 199,081 total - Sale
Common Stock
[F1][F4]2026-02-17$123.93/sh−3,556$440,690→ 195,525 total - Sale
Common Stock
[F1][F5]2026-02-17$124.66/sh−2,281$284,343→ 193,244 total - Sale
Common Stock
[F1]2026-02-17$126.34/sh−1,161$146,681→ 192,083 total
- 450,281(indirect: By Trust)
Common Stock
[F6]
Footnotes (6)
- [F1]Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.